|1.||Ohashi, Y: 2 articles (01/2003 - 10/2000)|
|2.||Tominaga, T: 2 articles (01/2003 - 10/2000)|
|3.||Harvey, Harold A: 2 articles (08/2002 - 03/2002)|
|4.||Lipton, Allan: 2 articles (08/2002 - 03/2002)|
|5.||Fukuda, K: 2 articles (11/2001 - 08/2000)|
|6.||Yamamoto, M: 2 articles (11/2001 - 08/2000)|
|7.||Kitano, H: 2 articles (11/2001 - 08/2000)|
|8.||Taniguchi, H: 2 articles (11/2001 - 08/2000)|
|9.||Kokufu, I: 2 articles (11/2001 - 08/2000)|
|10.||Yano, T: 2 articles (11/2001 - 08/2000)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/1994 - "To resolve these issues, a double-blind randomised endocrine study of three doses of fadrozole hydrochloride [0.5 mg twice daily (bd); 1.0 mg bd; 2.0 mg bd] was conducted in 80 (68 evaluable) postmenopausal patients with advanced breast cancer over a period of 3 months. "
03/15/1990 - "In this Phase I trial, 16 heavily pretreated postmenopausal patients with metastatic breast cancer were treated with escalating doses of CGS 16949A from 0.6 to 16 mg total daily oral dose. "
06/01/1999 - "[Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer]."
03/01/1994 - "Thus, CGS16949A showed good efficacy, tolerability and usefulness in postmenopausal patients with advanced or recurrent breast cancer."
03/01/1994 - "From these results, it is concluded that CGS16949A seemed to be a useful hormonal agent in the treatment of postmenopausal breast cancer."
07/01/1996 - "Tumor size in the OCT+CGS 16949A group was significantly decreased compared with that in the OCT or CGS 16949A alone. "
06/01/1994 - "A daily treatment of 0.5 mg/kg CGS 16949A was more effective than the once every 7 days treatment of 14 mg/kg on the tumor growth. "
02/15/1988 - "Tumors, which were allowed to regrow after a first treatment with CGS 16949A, were similarly efficaciously suppressed with a second treatment with CGS 16949A. "
02/15/1988 - "treatment of tumor-bearing rats for 42 days with CGS 16949A at doses of 1.0 to 8.0 mg/kg caused almost complete regression of palpable tumors and almost totally suppressed the appearance of new tumors. "
09/16/1997 - "Also, we compared the effect of the non-steroidal aromatase inhibitor (CGS 16949A) on the inhibition of tumor growth. "
|3.||Neoplasm Metastasis (Metastasis)
06/01/1999 - "Eleven recurrent postmenopausal breast cancer patients with osseous or lung metastases were received fadrozole hydrochloride at a dose of 1 mg twice a day for more than 8 weeks. "
10/01/1999 - "Chemoendocrine therapies using 5'-DFUR or CMitF in addition to TAM and fadrozole hydrochloride hydrate had developed progressive disease for liver metastasis. "
02/01/1999 - "[A case of pleural and mediastinal lymph node metastases from breast cancer effectively treated with fadrozole hydrochloride in combination with cyclophosphamide]."
12/01/2001 - "[An elderly woman with breast cancer and multiple liver metastasis that responded well to combination therapy of fadrozole and tamoxifen]."
11/01/2001 - "Case 2: A 61-year-old woman was treated with CMF therapy, 5'-DFUR, tamoxifen, MPA fadrozole and pamidronate for bone metastasis and local recurrence. "
02/01/1996 - "The present study strongly indicates that the new selective aromatase inhibitor fadrozole should be useful for the treatment of endometriosis."
02/01/1996 - "Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats."
02/01/1996 - "The therapeutic effect of the new nonsteroidal aromatase inhibitor fadrozole hydrochloride (4-(5,6,7,8-tetrahydro-imidazo[1,5a]pyridin-5-yl)benzonitrile monohydrochloride, fadrozole, CAS 102676-31-3, CGS16949A) was assessed using a surgically induced endometriosis model in rats. "
03/01/1990 - "Two further patients treated with 2 mg twice a day experienced persistent nausea which improved after dose reduction, and one patient, treated with 0.3 mg twice daily, developed a vasculitic rash requiring discontinuation of CGS 16949A. "
06/15/1996 - "Adverse experiences were mild with both therapies, but megestrol acetate was associated wiht a higher frequency of weight gain, fluid retention and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting."
06/15/1996 - "There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. "
|9.||Megestrol Acetate (Borea)
|4.||Drug Therapy (Chemotherapy)